SUBSCRIBE
SUBSCRIBE

ALX Oncology

NEWS
Business
BioSpace Movers & Shakers, May 8
Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
May 7, 2020
 · 
5 min read
 · 
Alex Keown
Load More
JOBS
IN THE PRESS
Press Releases
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
May 30, 2025
 · 
1 min read
Press Releases
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
May 20, 2025
 · 
4 min read
Press Releases
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
May 14, 2025
 · 
2 min read
Press Releases
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 8, 2025
 · 
11 min read
Press Releases
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
May 2, 2025
 · 
1 min read
Press Releases
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
April 7, 2025
 · 
4 min read
Press Releases
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
March 5, 2025
 · 
6 min read
Press Releases
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
February 27, 2025
 · 
1 min read
Press Releases
ALX Oncology to Host Virtual R&D Day on March 5, 2025
February 18, 2025
 · 
1 min read
Press Releases
CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso,
January 29, 2025
 · 
5 min read
Load More